Precision Medicine in Oncology®

Gilteritinib generated comparable OS outcomes vs midostaurin in newly diagnosed FLT3-mutated AML, failing to meet the phase 3 trial primary end point.

Ziftomenib plus 7+3 yielded high CR and MRD-negativity rates with manageable safety in newly diagnosed NPM1/KMT2A-mutated AML.

Revumenib yielded responses across subgroups with relapsed/refractory, NPM1-mutated AML and co-mutations, as well as in KMT2A-rearranged acute leukemia.

Experts recap of the most pivotal lung cancer data to surface at the 2026 ASCO Annual Meeting.

The FDA has approved the FoundationOne CDx as a companion diagnostic for inavolisib in HR-positive/HER2-negative, PIK3CA-mutated breast cancer.

Pemigatinib improved PFS as first-line therapy for FGFR2-rearranged cholangiocarcinoma in the phase 3 FIGHT-302 trial.

FLAME data show ctDNA-guided addition of chemotherapy to osimertinib improved PFS vs osimertinib alone in EGFR-mutant NSCLC.

CIRCULATE provides the first prospective randomized evidence in support of a ctDNA-guided treatment escalation strategy in pMMR/MSS stage II colon cancer.

Encorafenib plus cetuximab and FOLFIRI improved PFS vs chemotherapy alone in first-line BRAF V600E–mutant metastatic colorectal cancer.

Adjuvant selpercatinib cut recurrence or death risk by 83% vs placebo in stage IB-IIIA RET fusion–positive NSCLC in LIBRETTO-432.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The FDA approved Dato-DXd for PD-1/PD-L1–ineligible triple-negative breast cancer, granted priority review to sevabertinib in HER2-mutant NSCLC, and more.

The top 5 OncLive TV videos of the week cover insights in breast cancer, acute myeloid leukemia, bladder cancer, multiple myeloma, and melanoma.

The FDA approved T-DXd in early HER2+ breast cancer, adjuvant atezolizumab in MRD+ MIBC, and more.

The FDA clears zenocutuzumab in NRG1 fusion+ cholangiocarcinoma, accepts a taletrectinib NDA in ROS1+ NSCLC for review, and more.

The FDA approved Guardant360 CDx as a companion diagnostic for vepdegestrant in ER-positive advanced or metastatic breast cancer with ESR1 mutations.

The FDA cleared vepdegestrant in ER+ breast cancer with ESR1 mutations, ODAC voted on key questions in breast and prostate cancer, and more.

The FDA approved vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after at least 1 line of endocrine therapy.

The FDA grants priority review to enfortumab vedotin-ejfv sBLAs in MIBC, the review period for subcutaneous isatuximab BLA in myeloma has been extended, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Tovorafenib has received conditional marketing authorization in Europe for patients at least 6 months of age with BRAF-positive relapsed/refractory pLGG.

The top 5 OncLive TV videos of the week cover insights in mantle cell lymphoma, endometrial cancer, salivary gland cancer, myeloproliferative neoplasms, and renal cell carcinoma.

The FDA granted priority review to an I-DXd BLA for extensive-stage small cell lung cancer, a sBLA for zenocutuzumab in NRG1+ cholangiocarcinoma has been submitted to the FDA, and more.

An sBLA seeking the approval of zenocutuzumab has been submitted to the FDA, and the agent was added to the NCCN guidelines for NRG1-positive cholangiocarcinoma.

The top 5 OncLive TV videos of the week cover insights in mantle cell lymphoma, chronic lymphocytic leukemia, salivary gland cancer, cholangiocarcinoma, and prostate cancer.